Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?

April 8, 2022
The FY2022 drug price revision this month saw the first price reductions under the early G1/G2 application rule, which is invoked for long-listed products (LLPs) seeing fast generic switches. A tally by Jiho found that authorized generics (AGs) have been...read more